Abstract
Antibiotic resistance is a growing problem worldwide. Of particular importance is the resistance of Mycobacterium tuberculosis (Mtb) to currently available antibiotics used in the treatment of infected patients. Up-regulation of an aminoglycoside (AG) acetyltransferase, the enhanced intracellular survival (Eis) protein of Mtb (Eis-Mtb), is responsible for resistance to the second-line injectable drug kanamycin A in a number of Mtb clinical isolates. This acetyltransferase is known to modify AGs, not at a single position, as usual for this type of enzyme, but at multiple amine sites. We identified, using in silico techniques, 22 homologues from a wide variety of bacteria, that we then cloned, purified, and biochemically studied. From the selected Eis homologues, 7 showed the ability to modify AGs to various degrees and displayed both similarities and differences when compared to Eis-Mtb. In addition, an inhibitor proved to be active against all homologues tested. Our findings show that this family of acetyltransferase enzymes exists in both mycobacteria and non-mycobacteria and in both pathogenic and nonpathogenic species. The bacterial strains described herein should be monitored for rising resistance rates to AGs.
Original language | English |
---|---|
Pages (from-to) | 272-283 |
Number of pages | 12 |
Journal | ACS Infectious Diseases |
Volume | 1 |
Issue number | 6 |
DOIs | |
State | Published - Jan 8 2016 |
Bibliographical note
Publisher Copyright:© 2015 American Chemical Society.
Keywords
- acetylation
- aminoglycoside acetyltransferases
- enzyme inhibitors
- n-propionylation
- sequential reactions
ASJC Scopus subject areas
- Infectious Diseases